Research and Publications

As well as my NHS and private practice, I remain at the forefront of research in my field as I believe this allows me to be as innovative and as informed as possible in prescribing treatments to my patients. I have been involved in the development of numerous publications, clinical trials and have contributed to book chapters.

Links

Google Scholar - Dr Khurum Khan
Read articles
National Library of Medicine (PubMed) - Dr Khurum Khan
Read articles
Research Gate - Dr Khurum Khan
Read articles

Publications

  • Hanna D, Chopra N, Hochhauser D, Khan K.H. The role of PARP inhibitors in gastrointestinal cancers. Critical Reviews Oncology and Haematology. 2022; PMID 35124199 (Comprehensive review). 

 

  • Rata M, Khan K.H, Collins D, Koh D-M, Tunariu N, Bali M, d’Arcy J, Winfield J, Picchia S, Valeri N, Chau I, Cunningham D, Fassan M, Leach M, Orton M. “DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases”. Cancer Imaging. 2021; 21(1):67 (Original paper).

 

  • Rao S, Guren MG, Khan K.H, Brown G, Renehan AG, Steigen SE, Deutsch E, Martinelli E, Arnold D. On behalf of the ESMO Guidelines Committee, Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-u. Annals of Oncolgy. 2021; doi: https:// doi.org/10.1016/j.annonc.2021.06.015. (European Guidelines).

 

  • Puglisi M, Molife L.R, Ja de Jonge M, Khan K.H, Doorn L, Forster M, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens F. A phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol. 2021; 17(21); 2747-2758. (Original paper).

 

  • Joharatnam-Hogan N, Khan K.H. Thermal ablation in colorectal liver metastases- the paradox of equipoise. Hepatobiliary Surg Nutr. 2021; 10(2):276-278. (Editorial).  

 

  • Fernando S, Veli M, Mohammadi B, Khan K.H. COVID-19 and its impact on Upper Gastrointestinal (GI) Cancer Management. Cancers. 2021; 13(3):397. (Comprehensive review).  

 

  • Joharatnam-Hogan N, Wilson W, Shiu K, Fusai G, Davidson B, Hochhauser D, Bridgewater J, Khan K.H. Multimodal treatment in metastatic colorectal cancer improves outcomes: A University College London Hospital Experience). Cancers. 2020;27:3545. (Original Paper).  

 

  • Crolley V, Hanna D,  N Joharatnam-Hogan, Chopra N, Bamac E, Desai M, Lam Y, Dipro S, Kanani R, Benson J, Wilson W, Fox T, Shiu K, Forster M,  Bridgewater J, Hochhauser D, and Khan K.H. COVID-19 in cancer patients on anti-cancer systemic therapies- outcomes from CAPITOL (COVID-19 CAncer PatIenT Outcomes in North London). Therapeutic Advances in Medical Oncology. 23;12:1758835920971147. (Original Paper).

 

  • N Joharatnam-Hogan, Hochhauser D, Shiu K, Rush H, Crolley V,  Wilson W, Sharma A, Muhammad A, Anwar M, Vasdev N, Goldstein R, Kanster G, Saha A, Raja F, Bridgewater J, and Khan K.H. Outcome of the 2019 Novel Coronavirus in patients with or without a history of cancer- a multi-centre North London experience. Therapeutic Advances in Medical Oncology. 2020; 14(2):14; 12:1758835920956803. doi: 10.1177/1758835920956803.  (Original Paper).

 

  • Khan K.H, Gonzalez E, Cunningham D, Koh D-M, Woolston A, Griffiths B, Kouvelakis K, Calamai V, Bali M, Khan N, Bryant A, Saffery C, Dearman C, Begum R, Rao S, Starling N, Watkins D, Chau I, Braconi C, Valeri N, Gerlinger M, Fotiadis N. Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in specialist cancer centre with prospective validation within clinical trial data. Frontiers in Oncology. 2020; 10:1634 (Original paper).

 

  • N Joharatnam-Hogan, Khan K.H. Covid-19 Cancer Conundrum- Evidence driving decisions or the lack of it? BMC Medicine. 2020; 18(2): 182.  (Expert Commentary).

 

  • Abdul-Latif M, Townsend K, Dearman C, KK Shiu, Khan K.H. Immunotherapy in Gastrointestinal Cancers: The current scenario and future perspectives. Accepted by Cancer Treatment Reviews in May 2020. (Solicited review).

 

  • Khan K.H, N Cascinu S, Cunningham D, Kim S, Oki E, Seery T, Shen L, Siena S, Tournigand C, Serdar T, Hendlisz H. Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. Cancer Treatment Reviews. Accepted in April 20. (Solicited review).

 

  • N Joharatnam-Hogan, KK Shiu, Khan K.H. Challenges in the treatment of gastric cancer in the older patient. Cancer Treatment Reviews. Feb 10;85:101980, doi: 10.1016/j.ctrv.2020.101980. (Solicited review).

 

  • N Joharatnam-Hogan, Khan K.H. Expert commentary on “Intensive routine follow-up after bowel cancer treatment may not be necessary”.doi: 10.3310/signal-000869, Published on 29 January 2020. (Expert commentary).

 

  • Khan K.H, Valeri N, Dearman C, Rao S, Watkins D, Starling N, Chau I, Cunningham D. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. Critical Reviews Oncology and Haematology.2019;143:153-163. (Comprehensive review).

 

  • Woolston A*, Khan K.H*, Spain G*, Barber L*, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies M, Furness A, Sclafani F, Peckitt C, Jiménez M, Semiannikova M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F,  Guettler S, Von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, and Gerlinger M. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer. Cancer Cell. 2019; 36(1): 35-50. (Original paper).

 

  • Anandappa G, Lampis A, Cunningham D, Khan K.H, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki E, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, Bryant A, Hahne J, Chau I,  Fassan S, and Valeri N. MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research. 2019; 1;25:3830-3838. (Original paper).

 

  • Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K.H, Barber L, Woolston A, Spain G, Von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M. CEA Expression Heterogeneity and Plasticity Confer Resistance to the CEA-Targeting Bispecific Immunotherapy Antibody Cibisatamab (CEA-TCB) in Patient-Derived Colorectal Cancer Organoids. Journal for ImmunoTherapy of Cancer. 2019; 7(1): 101. 

 

  • Janssen Q. Buettner S, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K.H, Kim K, Kim S, Kim SS, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S, Okada K, Paniccia A, Parikh P, Peters N, Rabl H, Samra J, Tinchon C, Tienhoven G, Veldhuisen E, Wang-Gillam A, Weiss M, Wilmink J, Yamaue H, Homs M, Eijck C, Katz M, and Koerkamp B. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: A systemic review and patient-level meta-analysis. Journal of the National Cancer Institute. 2019; 111(8): 782-794 (Meta-analysis). 

 

  • Khan K.H, Rane J, Cunningham D, Chau I, Rao S, Watkins D, Starling N, Kalaitzaki E, Foster M, Braconi C, Valeri N, Gerlinger M, and Chau I. Efficacy and cardiotoxic safety profile of Raltitrexed in Fluorouracil pre-treated or high-risk cardiac patients with GI malignancies- A large single-centre experience. Clinical Colorectal Cancer. 2019;18(1):64-71. (Original paper). 

 

  • Wagner S, Vlachogiannis G, Brandon A, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust A, Matthews N, Eason K, Khan K.H, Starling N, Cunningham D, Sadanandam A, Isacke C, Kirkin V, Valeri N and Whittaker S. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene. 2019; 38(10):1717-1733. (Original paper).

 

  • Khan K.H, Cunningham D, Werner B, Koh DM, Vlachogiannis G, Spiteri I, Heide T, Mateos J, Vatsiou A, Lampis A, Damavandi M, Lote H, Huntingford I, Hedayat S, Chau I,  Bali M, Khan N, Bryant A, Saffery C, Begum R, Rao S, Starling N, Watkins D, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jone T, Proszek P, Fassan M, Hahne J, Hubank M,  Braconi C, Sottoriva A, Valeri NC. Forecasting the evolution of resistance to targeted treatment in metastatic colorectal cancer using longitudinal matched tissue and liquid biopsies in a prospective clinical trial. Cancer Discovery. 2018; 8(10):1270-1285. (Original paper). 

 

  • Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang J, Chenard-Pririer, Collins D, Lim J, Ameratunga M, Khan K.H, Kaye S, Banerji U, Lopez J, George A, de Bono J, and van der Graaf. “Adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials, clinical outcome and recommendations”. European Journal of Cancer. 2018; 9(101):55-61. (Original paper). 

 

  • Smyth E, Khan K.H, Valeri N. Translational research and application of basic biology to clinical trial development in GI cancers. Annals of Translational Medicine. 2018; 6(9): 164. (Solicited review).

 

  • Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K.H, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri NC. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378): 920-926. (Original paper).

 

  • Lampis A, C Cunningham D, Aitken K, and Rao S. Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos J, Begum R,  Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali M, Nepal C, Khan K.H, Stubbs M, Hahne J, Gasparini P, Guzzardo V, Croce C, Eccles S, Fassan M, Cunningham D, Andersen J, Workman P, Valeri N, Braconi C. microRNA 21 Promotes Resistance of Cholangiocarcinomas to Heat Shock Protein 90 Inhibitors. Gastroenterology. 2018; 154(4): 1066-1079 (Original paper).

 

  • Khan K.H, Cunningham D, Aitken K, and Rao S. In reply to “Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised CEA Levels in Colorectal Cancer Following PET-CT Imaging”. Oncologist. 2017; 22(11): 1411-1412. (Letter to editor).

 

  • Khan K.H, Rata M, Cunningham D, Koh D-M, Tunariu N, Hahne J, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi M, Lote H, Williams A, Eccles S, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, & Valeri. “Radiological and circulating biomarkers of response to Regorafenib in treatment-refractory metastatic colorectal cancer patients in a PROSPECTive phase II study (PROSPECT-R)”. GUT. 2018; 67(8):1484-1492 (Original paper).

 

  • Magness A, Squires J, Griffiths B, Khan K.H, Swain A, Willison K, Cunningham D, Gerlinger M, Klug D. “Multiplexed single cell protein expression analysis in solid tumours using a miniaturised microfluidic assay”. Converg Sci Phys Oncol. 2017; 3(2017): 02003 (Original paper).

 

  • Khan K.H, Athauda A, Aitken K, Cunningham D, Watkins D, Starling N, Cook G, Kalaitzaki E, Chau I and Rao S. Survival Outcomes in Asymptomatic Patients with Normal Conventional Imaging but Raised CEA Levels in Colorectal Cancer Following PET-CT Imaging. Oncologist. 2016; 21(12): 1502-1508 (Original paper- featured article).

 

  • Khan K.H, Wong M, Rihawi K, Bodla S, Morganstein D, Kaye S, Banerji U, and Molife R. Hyperglycaemia and PI3K, AKT and mTOR inhibitors in phase I trials: incidence, predictive factors and management. Oncologist. 2016; 21(7): 855-60 (Original paper).

 

  • Smyth E, Khan K.H, and Cunningham D. AREG and EREG as Predictive Biomarkers for RAS Wild-Type Colorectal Cancer Treated With Panitumumab: A Fresh Approach to an Old Puzzle. JAMA Oncology. 2016; Feb 11. doi: 10.1001/jamaoncol.2015.6274 (Editorial).

 

  • Khan K.H, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C and Chau I. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the Pancreatic cancer Erbitux, Radiotherapy and UFT (PERU) trial. Oncotarget. 2016; 7(11): 12672-12681 (Original paper).

 

  • Khan K.H, Yap T, Ring A, Molife L, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, De Bono J, and Kaye. Phase I trials in older patients with advanced solid tumours. Br J Cancer. 2016; 114(3): 262-268 (Original paper).

 

  • Khan K.H, Cunningham D, Chau I. Targeting Angiogenic Pathway in Colorectal Cancer: Complexities, Challenges and Future Directions. Curr Drug Targets. 2016; 18(1): 56-71 (Solicited review).

 

  • Khan K.H, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D, Chau I. Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. BMC Cancer. 2015; 15(1): 15 (Original paper).

 

  • Tolcher A, Khan K.H, Ong M, Papadimitrakopoulou V, Gandara D, Patnaik A, Baird R, Garrett C, Skolnik J, Rubin E, Smith P, Huang P, Learoyd M, Shannon K, Morosky A, Tetteh E, Jou Y,  Papadopoulos K, Moreno V, Kaiser B, Yan L, de Bono J.  Antitumor activity in RAS-driven tumours by blocking AKT and MEK: Proof of concept preclinical and clinical data. Clin Cancer Res. 2015; 21(4): 739-748 (Original paper).

 

  • Roulstone V, Khan K.H, Pandha H, Rudman S, Coffey M, Gill G, Melcher A, Vile R, Harrington K, de Bono J, Spicer J. Phase I trial of cyclophoshamide as immune modulator for optimising oncolytic reovirus delivery to solid tumors. Clin Cancer Res. 2015; 21(6): 1305-1312 (Original paper).

 

  • Moorcraft S, Khan K.H, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA); clinical outcomes and prognostic factors, The Royal Marsden (RM) experience. Clin Colorectal Cancer. 2014; 13(4): 232-238 (Original paper).

 

  • Cutsem EV, Prager G, Sargent D, Byrne A, Huber H, Middleton G, Khan K.H, Mattos-Arruda L, Seufferlein T. Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of OncoPathology. 2014; 2(4): 37-45 (Solicited review).

 

  • Khan K.H, Wale A, Brown G, Chau I. Colorectal cancer with liver metastases: chemotherapy, surgical resection first or palliation alone? World journal of gastroenterology. 2014; 20(35): 12391-12406 (Solicited review).

 

  • Khan K.H, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife R, Banerji U, de Bono J, Cunningham D, Kaye SB. Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer. 2014; 17(4): 621-629 (Original paper). 

 

  • Khan K.H, Blanco C.B, L R Molife. Cancer Therapeutics: Targeting the Apoptotic Pathway. Crit Rev Oncol and Haematol. 2014; 90(3); 200-219. (Comprehensive un-solicited review).

 

  • Khan K.H, Hanna G, Campbell L, Scullin P, Hussain A, Stranex S, Eakin RL and McAleese J. Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer. C Journal of Cancer. 2013; 32(10): 539-545 (Original paper).

 

  • Khan K.H, Yap T.A, Yan L, and Cunningham D.  Targeting the PI3K-AKT-mTOR signalling network in cancer.  C Journal of Cancer. 2013; 32(5), 253-265 (Solicited review).

 

  • Khan K.H, R Goody, H Hameed, V Coyle and JJA McAleer.  Metastatic Melanoma, a regional review and future directions.  Tumori. 2012; 98(5): 575-580 (Original paper).

 

  • Khan K.H, A Fenton, E Murtagh, JJA McAleer and A Clayton.  Reversible Posterior Encephalopathy after sunitinib therapy. Tumori. 2012; 98(5), 139-142 (Case report and literature review).

 

  • Khan K.H, MA Rathore, MI Bhatti, E Hand, D Allen, M Ismail, TCK Tham, V Laughlin.  Retrospective analysis of resected primary colorectal cancer revealed no correlation between node harvest and node involvement.  J Pak Med Assoc. 2011; 61(12): 1202-1205. (Original paper).

 

  • Sharif M, Trinick T, and Khan.K.H.  Identification of internal carotid artery dissection with migraine—case report and literature review.  J Pak Med Assoc. 2010; 60(2); 131-133 (Case report and literature review).

 

  • Khan K.H and Tham T.C. Neuroleptic malignant syndrome induced by quetiapine overdose. Br J Hosp Med (Lond). 2008; 69(3), 171-172 (Case report and literature review).

 

  • Shirmeen A, Khan MF, Khan KH and Khan K.H.  Assessment of fertility control efforts in a selected area of Karachi, Pakistan.  Ulster Med J. 2006; 76(3): 144-145 (Original paper).

 

  • Khan K.H. White-coat effect or more than that!  Ir Med J. 2016; 99(10): 315 (Letter).

 

  • Khan K.H. What medicine is really about?  British Medical Journal. 2006; 332(7544): 776 (Filler).

Book Chapters

  • Khan K.H, Seymour M, Ring A, Johnson P. Clinical trials in older patients. In Problem solving in Older Cancer Patients. Ring A, Harari D, Kalsi T, Mansi J, and Selby P (Eds). Evidence-based Networks Ltd. 2016: 26-30.

 

  • Ashenden M, Khan K.H, Barber L, Gerlinger M. Mutations, Genomic Instability, and Cancer Evolution. In ESMO Handbook of Translational Research. Tortora G, Sessa C, Scarpa A, Banerjee S (Eds). ESMO Publishing Working Group. 2015: 81-91.

 

  • Khan K.H and Maisey N. Colorectal Liver Metastases. In Challenging Concepts in Oncology. Bhattacharyya M, Payne S, and McNeish I (Eds). OUP Oxford. 2015: 121-132.

 

  • Gonzalez M, Khan K.H and Basu B. Clinical trials. In Oxford Case Histories in Oncology. Ajithkumar T, Harnett A and Roques T (Eds). OUP Oxford. 2014: 257-261.

Abstracts

  • Lee R, Wysocki O, Zhou C, Calles A, Eastlake L, Ganatra S, Harrison M, Horsley L, Huddar P, Khan K.H, McKenzie H, Palmieri C, Revuelta J, Thomas A, Wilson C, Cooksley T, Dive C, Freitas A, Armstrong A. Outcomes for cancer patients on systemic anti-cancer therapies during CORONET; COVID-19 in Oncology evaluation Tool: Use of machine learning to inform management of COVID-10 in patients with cancer. In: Proceedings of ASCO. 

Virtual presentation selected for oral presentation at the Annual meeting of the ASCO; 2021 June.

 

  • Crolley V, Hanna D, N Joharatnam-Hogan, Chopra N, Bamac E, Desai M, Lam Y, Dipro S, Kanani R, Benson J, Wilson W, Fox T, Shiu K, Forster M, Bridgewater J, Hochhauser D, and Khan K.H. Outcomes for cancer patients on systemic anti-cancer therapies during COVID-19 pandemic from the CAPITOL (COVID-19 CAncer PatIenT Outcomes in North London) cohort study. In: Proceedings of ASCO. 

Virtual presentation selected for merit award at the Annual meeting of the ASCO; 2021 June.

 

  • N Joharatnam-Hogan, W Wilson, K Shiu, G Fusai, B Davidson, D Hochhauser, J Bridgewater, Khan K.H. Multimodal treatment in metastatic colorectal cancer improves outcomes: A University College London Hospital Experience. In: Proceedings of ESMO. 

Virtual presentation at the Annual meeting of the ESMO; 2020 July.

 

  • Hedayat S, Lampis A, Vlachogiannis G, Khan K.H, Cunningham D, Marchetti S, Fassan M, Hahne J, Begum R, Schirripa M, Loupakis F, and Valeri N. 10P Circulating miR-652p as biomarkers of drug resistance in metastatic colorectal cancer patient. In: Proceedings of: Proceedings of the AACR. 

Virtual presentation at the Annual meeting of the AACR; 2020 June 24th-29th April; San Diego, California.

 

  • Hedayat Khan K.H, Cunningham D, Vlachogiannis G, Lampis A,  Marchetti S, Fassan M, Begum R, Schirripa M, Loupakis F, and Valeri N. Circulating miR-652-3p as biomarkers of resistance to regorafenib in metastatic colorectal cancer patient. In: Proceedings of 50th Anniversary of EACR25; 29th June -3rd July 2018. 

Oral presentation at the NanoString Summit; 2018 18th October; London, UK. 

 

  • Anandappa G, Lampis A, Cunningham D, Kouvelakis K, Khan K.H, Vlachogiannis G, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Peckitt C, Thomas J, Rana I, Begum R, Bryant A, Hahne J, Chau I,  Fassan S, Valeri N, and Duncan J. Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC). In: Proceedings of the GI ASCO; 2019. J Clin Oncol. 37 (4S): Abstract 548. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2019 Jan 17-19; San Francisco, CA.

 

  • Gonzalez- Exposito R, Semmianikova M, Griffiths B, Khan K.H, Barber L, Woolston A, Spain G, von Loga K, Swain A, Thomas J, Bryant A, Mansfield D, Rao S, Watkins D, Chau I, Starling N, Wallberg F, Cunningham D, and Gerlinger M. CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids. In: Proceedings of the GI ASCO; 2019. J Clin Oncol. 37 (4S): Abstract 535. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2019 Jan 17-19; San Francisco, CA. 

 

  • Patel U, Khan K.H, McDonagh E, Cunningham D, Koh D, and Bali M. Dual Energy CT Iodine Maps for Response Assessment in Colorectal Liver Metastases (CLM) Treated with a Multikinase Inhibitor (MKI) with Anti-Angiogenic Activity. In: Proceedings of Radiological Society of North America 2018 Scientific Assembly and Annual meeting; 2018. archive.rsna.org/2018/18014571.html. 

Poster presented at the Annual Meeting of the RSNA; 2018 Nov 25-30; Chicago, IL. 

 

  • Khan K.H, Woolston A, Spain G, Barber L, Patil, Griffiths B, Gonzalez- Exposito R, Mansukhani S, Davies M, Rao S, Watkins D, Sclafani F, Suntharanathan J, Peckitt C, Begum R, Rana I, Thomas J, Bryant A, Wotherspoon A, Fotiadis N, Khan N, Guettler S, von Loga K, Starling N, Chau I, Sadanandam A, Cunningham D, and Gerlinger M. Drivers of primary and acquired anti-EGFR resistance in colorectal cancer in the PROSPECT-C biomarker trial. In: Proceedings of the AACR; Cancer Res 2018; 78(13): Abstract 4339.

Poster presented at the Annual Meeting of the American Association for Cancer Research; 2018 Apr 14-18; Chicago, IL.

 

  • Hedayat S, Vlachogiannis G, Khan K.H, Marchetti S, Fassan M, Lampis A, Hahne J, Begum R, Cunningham D, and Valeri N. MicroRNA as biomarkers of resistance to regorafenib in metastatic colorectal cancer patient. In: Proceedings of 50th Anniversary of EACR25; 29th June -3rd July 2018. 

Oral presentation at the Annual meeting of the European Association of Cancer Research; 2018 June 29th-3rd July; Amsterdam, Holland.

 

  • Hedayat S, Vlachogiannis G, Jamin Y, Khan K.H, Fernandez-mateos J, Hahne J, Fassan S, Eccles S, Robinson S, Cunningham D, and Valeri N. Metastatic Colorectal Cancer (mCRC) Patient Derived Organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs. In: Europ J of Surg Oncol. 2017. 44 (11): Abstract S32.

Oral presentation at the National Cancer Research Institute (NCRI) conference; 2017 Nov 5-8, Liverpool, UK. (NCRI Prize Award for abstract). 

 

  • Hedayat S, Vlachogiannis G, Jamin Y, Khan K.H, Fernandez-mateos J, Hahne J, Fassan S, Eccles S, Robinson S, Cunningham D, and Valeri N. Metastatic Colorectal Cancer (mCRC) Patient Derived Organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs. In: two meetings.

Oral presentation at the Gene & Cancer Annual meeting; 2017 Apr 10-12; Cambridge, UK.

Poster presentation at the Cancer Precision Medicine; 2017 Mar 12-16; Amsterdam, Netherland.

 

  • Khan K.H, Cunningham D, Vlachogiannis G, Hedayat S, Rata M, Koh DM, Tunariu N, Jamin Y, Collins D, Chau I, Rao S, Watkins D, Starling N, Peckitt C, Fotiadis N, Saffery C, Hahne J, Fassan M, Braconi C, Valeri N. Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial. In: Proceedings of ESMO; 2017. Annals of Oncol. 28 (5S): Abstract 116p.

Poster presented at the European Society Medical Oncology Annual Conference; 2017 Sept 8-12. Madrid, Spain.

 

  • Khan K.H, Gonzalez E, Cunningham D, Koh D-M, Woolston A, Kouvelakis K, Bali M, McCall J, Khan N, Chau I, Valeri N, Gerlinger M, Fotiadis N. Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominantly gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. In: Proceedings of the GI ESMO Conference; 2017. Annals of Oncol. 28 (3S): Abstract PD-015.

Poster presented at the 19th World Congress on Gastrointestinal Cancer; 2017 28 Jun – 01 Jul, Barcelona, Spain.

 

  • Sundar R, McVeigh T, Petruckevitch, Diamantis N, Ang J, Chenard-Poirier M, Collins D, Lim J, Ameratunga M, Khan K.H, Kaye, S, Banerji U, Lopez J, DeBono J, Der Graaf W. Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials. In: Proceedings of ASCO; 2017. J Clin Oncol. 35 (15S): Abstract 293.

Poster presented at the American Society of Clinical Oncology Annual Conference; 2017 June 1-4. Chicago, IL.

 

  • Khan K.H, Rata M, Koh D-M, Tunariu N, Vlachogiannis G, Hahne J, Jamin Y, Collins D, Chau I, Rao S, Watkins D, Starling N, Kalaitzaki E, Fotiadis N, Begum R, Temple E, Fassan M, Chau I, Braconi C, Cunningham D and Valeri N. Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts). In: Proceedings of the GI ASCO; 2017. J Clin Oncol. 35 (4S): Abstract 613. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2017 Jan 18-21; San Francisco, CA.

 

  • Orton M, Jerome N, Rata M, Collins D, Khan K.H, Tunariu N, Cunningham D, Feiweier T, Koh D-M, Leach M. On the feasibility of data-driven estimation of Markov random filed parameters for IVIM modelling of abdominal DW-MRI: insights into which parameters can be reliably estimated from clinical data. In: Proceedings of 24th International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meetings & Exhibition, Volume: 24.

Poster presented at the Annual Meeting of the ISMRM Annual Meetings & Exhibition; 2016 May 7-13; Singapore. 

 

  • Khan K.H, Rata M, Koh D-M, Tunariu N, Collins D, Chau I, Watkins D, Starling N, Rao S, Peckitt C, Fotiadis N, Begum R, Saffery C, Thomas J, Gerlinger M, Valeri N, Watkins D, Cunningham D. A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC): initial magnetic resonance imaging (MRI) sub study results. In: Proceedings of GI ASCO; 2016. J Clin Oncol. 34 (4): Abstract 580. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2016 Jan 21-23; San Francisco, CA.

 

  • Khan K.H, Chau I, Gerlinger M, Valeri N, Koh D-M, Starling N, Watkins D, Rao S, Tunariu N, Fotiadis N, Begum R, Saffery C, Cunningham D. PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC). In: Proceedings of the 17th ESMO World Congress on Gastrointestinal Cancer; 2015. Ann of Oncol. 26 (5): Abstract P-309.

Poster presented at the World Congress on Gastrointestinal Cancer Annual Conference; 2015 Jul 1-4, Barcelona, Spain.

 

  • Khan K.H, Vlachogiannis G, Cunningham D, Hahne J, Darvish-Damavandi M, Barton S, Trevisani F, Mentrast G, Peckitt C, Lampis A, Braconi C, Khan N, Begum R, Starling N, Rao S, Watkins D, Bryant A, Chau I, Valeri N. “Validation of the role of circulating tumour DNA (ctDNA) in tracking mechanisms of resistance to Anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial”. In: Proceedings of the AACR; Cancer Res 2015; 75(15): Abstract 3589.

Poster presented at the Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA.

 

  • Moorcraft S, Khan K.H, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA); clinical outcomes and prognostic factors, The Royal Marsden (RM) experience. In: Proceedings of GI ESMO conference; Annals of Oncol 2014; 25(2): Abstract P-0111.

Poster presented at the 16th World Congress on Gastrointestinal Cancer; 2014 Jun 25-28, Barcelona, Spain.

 

  • Khan K.H, Peckitt C, Sclafani F, Trivedi S, Jain V, Stanway S, Cunningham D, Chau I. Fifteen year experience of all patients with small bowel adenocarcinoma (SBA), treated in a specialised gastrointestinal (GI) Oncology unit: Royal Marsden (RM) experience. In: Proceedings of the GI ASCO; 2014. J Clin Oncol. 32 (3S): Abstract 316. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2014 Jan 16-18; San Francisco, CA.

 

  • Khan K.H, Wale A, McCall J, Wijesejera N, Khan N, Chau I, Brown G. The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience. In: Proceedings of the GI ASCO; 2014. J Clin Oncol. 32 (3S): Abstract 622. 

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2014 Jan 16-18; San Francisco, CA.

 

  • Khan K.H, Molife L, Bodla S, Zivi A, Smith A, Ang J, Judson I, Banerji U, de Bono J, Kaye S. Phase I trials in patients (pts)>65 years with advanced solid tumours: Do they fare worse than younger pts? In: Proceedings of the European Cancer Congress (ECCO-ESMO-ESTRO); 2013. Eur Jour of Cancer. 49(S345).

Poster presented at ECCO-ESMO-ESTRO Cancer Conference; 2013 Sep 27-30; Amsterdam, Netherlands.

 

  • Wong M, Khan K.H, Rihawi K, Bodla S, Amin B, Shah K, Morganstein D, Kaye S, Banerji U, and Molife R. Factors predisposing to development of hyperglycaemia in phase 1 studies involving PI3K, mTOR, AKT and mTORC1 and mTORC2 inhibitors. In: Proceedings of the European Cancer Congress (ECCO-ESMO-ESTRO); 2013. Eur Jour of Cancer. 49(S180).

Poster presented at ECCO-ESMO-ESTRO Cancer Conference; 2013 Sep 27-30; Amsterdam, Netherlands.

 

  • Khan K.H, Young A, Mateo J, Tunariu N, Yap TA, Tan D, Mansfield D, Wong M, Riisnaes R, Harrington KJ, de Bono J. Clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. In: Proceedings of the ASCO; 2013. J Clin Oncol. 31 (15S): Abstract 3062. 

Poster presented at the American Society of Clinical Oncology Annual Conference; 2013 May-June 31-3. Chicago, IL.

 

  • Khan K.H, Ang J.E, Starling N, Shah K.J, Molife L,R, Banerji U, de Bono J, Cunningham D, Kaye S.B. Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist phase I unit. In: Proceedings of the GI ASCO Conference; 2013. J Clin Oncol. 34 (4S): Abstract 45.

Poster presented at the Annual Meeting of the Gastrointestinal American Society of Clinical Oncology; 2013 Jan 19-21; San Francisco, CA.

 

  • Khan K.H, Yan L, Mezynski J, Patnaik A, Moreno V, Papadopoulos K, Garrett C, Ong M, Shannon K, Morosky A, Zazulina V, Rubin E, Skolnik J, Smith I, Ryan J, Smith P, Learoyd M, de Bono J, Tolcher A. A Phase I dose escalation study of MK-2206 (Allosteric AKT inhibitor) with oral selumetinib (AZD6244) (MEK inhibitor) in patients with advanced or metastatic tumors. In: Proceedings of the ASCO; 2012. J Clin Oncol. 30 (15S): eAbstract 13599.

eAbstract presented at the American Society of Clinical Oncology Annual Conference; 2012 June 1-5. Chicago, IL.

 

  • Mateo J, Ong M, Pope L, Cassidy AM, Yap T, Perkins G, Riisnaes R, Flohr P, Thway K, Gonzalez M, Saeed S, Young AM, Toloui H, Khan K.H, Moran K, Ng M, Molife LR, Kaye SB, Banerji U, and De Bono JS. Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration of phase I trials. In: Proceedings of the ASCO; 2012. J Clin Oncol. 30 (30S): Abstract 6.

Poster presented at the American Society of Clinical Oncology Annual Conference; 2012 June 1-5. Chicago, IL.

 

  • Khan K.H, R Goody, H Hameed, V Coyle and JJA McAleer. Metastatic Melanoma, a regional review and future directions. In: Proceedings of the European Cancer Congress (ECCO-ESMO-ESTRO); 2011. Eur Jour of Cancer. 47(S658): Abstract 9319.

Poster presented at ECCO-ESMO-ESTRO Cancer Conference; 2011 Sep 23-27; Stockholm, Sweden.

 

  • Khan K.H, Scullin P, Hussain A, Stranex S, Eakin RL and McAleese J. Re-Challenge of Gemcitabine/Carboplatin chemotherapy in second line setting in Non-Small Cell Lung Cancer patients. In: Proceedings of the BTOG Conference; 2010. Abstract 163. Lung Cancer. 67(S1): Abstract 20.

Poster presented at 8th British Thoracic Oncology Group Conference. 2010 Jan 27-29, Dublin. 

 

  • Khan K.H, MA Rathore, MI Bhatti, E Hand, D Allen, M Ismail, TCK Tham, V Laughlin. Retrospective analysis of resected primary colorectal cancer revealed no correlation between node harvest and node involvement.  In: Proceedings of the European Cancer Congress (ECCO-ESMO-ESTRO); 2011. Eur Jour of Cancer. 7(S2): Abstract 6017.

Poster presented at ECCO-ESMO-ESTRO Cancer Conference; 2009 Sep 20-24; Berlin, Germany.

 

  • Khan K.H, Kinnear SR and Caddy GR. Retrospective observational study of the patients admitted with upper GI bleed. In: Proceedings of the AGA Institute and Digestive Disease Week; 2008. Gastroenterology. 134(4): Abstract 332.

Oral presentation at AGA Institute and Digestive Disease Week; 2008 May 17-22; San Diego, CA.